Bristol Myers Squibb announced Thursday that its blockbuster checkpoint inhibitor Opdivo hit the primary endpoint in the Phase III CheckMate-76K trial for a particularly intractable form of melanoma.
Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.
Novavax Inc. said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.
World Health Organization head Tedros Adhanom Ghebreyesus said on Wednesday a clinical trial of vaccines that could potentially combat the Sudan strain of Ebola driving an outbreak in Uganda could start within weeks.
Data from an ongoing Phase III trial showed Sanofi/Regeneron’s Dupixent (dupilumab) can induce histological disease remission in young eosinophilic esophagitis (EoE) patients ages 1–11 years, the companies announced Tuesday.
The company’s expansion into clinical trial recruitment could bring it new streams of revenue from drug companies.
Merck & Co said a therapy it gained through the drugmaker’s $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.
Life-threatening safety concerns prompted KalVista Pharmaceuticals to shut down a mid-stage clinical trial for hereditary angioedema, the swelling of skin in response to an allergic reaction, the company announced Tuesday.
Intercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing goal – preventing dementia even before symptoms start.
